Article

STAAR Surgical receives CE mark for preloaded lens injector system

STAAR Surgical announced that it has received CE mark approval for its proprietary foldable IOL injector system (KS-X preloaded hydrophobic acrylic injector), which is used in minimally invasive cataract surgery procedures.

Monrovia, CA

-STAAR Surgical announced that it has received CE mark approval for its proprietary foldable IOL injector system (KS-X preloaded hydrophobic acrylic injector), which is used in minimally invasive cataract surgery procedures.

The approval allows the company, which has offered the device in the Japanese market for 2 years, to market the delivery system in the European Union and other countries that recognize the CE mark. The approval also signifies that the system complies with applicable safety and quality standards, according to a prepared statement issued by the company.

“Receipt of the CE mark is an important accomplishment and a validation of STAAR Japan’s expertise in the development of preloaded delivery systems for foldable IOLs that enable precise delivery of the lens during cataract surgeries,” said David Bailey, president of international operations at STAAR Surgical.

“The outstanding functionality of our preloaded system has already won market share in the more difficult silicone segment, and this approval allows us to bring the technology to the growing number of surgeons who prefer the hydrophobic acrylic lenses for their patients,” he continued. “With the introduction of this product in these markets, we believe we are moving toward our goal of establishing our preloaded delivery systems as the global standard of care in all IOL lens segments.”

The first shipments of the product in key European and Australian markets are expected to begin late this month. The device is not approved for sale in the United States.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.